INHBA: The Potential Drug Target and Biomarker for Inhibiting Inhibin Beta A Subunit

Target Name: INHBA

NCBI ID: G3624

INHBA: The Potential Drug Target and Biomarker for Inhibiting Inhibin Beta A Subunit

INHBA, or Inhibin beta A subunit, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It plays a critical role in the regulation of water and electrolyte balance, and is also involved in the development and maintenance of blood pressure.

Recent studies have identified INHBA as a potential drug target and biomarker for a variety of diseases, including heart failure, hypertension, and neurodegenerative disorders. This is due to INHBA's unique structure and function, as well as its expressed expression in multiple tissues, which makes it a promising candidate for targeting with small molecules.

One of the key challenges in developing INHBA as a drug target is its complex biology. INHBA is a 14-kDa protein that contains four transmembrane domains and a cytoplasmic tail. It is involved in various signaling pathways, including the regulation of ion channels, cytoskeletal organization, and cell adhesion.

Additionally, INHBA is a protein that is expressed in a variety of tissues, making it difficult to target with small molecules. However, recent studies have identified a small molecule that can inhibit INHBA and modulate its expression levels. This compound, known as ITAC-101, is a peptidomimetic inhibitor of the ion channel K channels, which are involved in the regulation of INHBA function.

ITAC-101 has been shown to modulate INHBA expression levels in various tissues, including the brain, heart, and kidneys. It also appears to have a beneficial effect on various physiological processes, including blood pressure, ion balance, and neurodegenerative disorders.

Another potential drug target for INHBA is its role in the regulation of pain. INHBA is involved in the regulation of pain signaling, and has been shown to play a critical role in the development of neuropathic pain.

Research has shown that INHBA is involved in the regulation of pain perception, neurotransmitter release, and behavioral state. It is also involved in the modulation of pain modalities, including thermal and chemical pain.

There is a growing interest in developing INHBA as a drug target for pain management, due to its unique structure and function, as well as its expressed expression in multiple tissues. This makes it a promising candidate for targeting with small molecules, and could lead to new treatments for neuropathic pain.

In conclusion, INHBA is a protein that is involved in various signaling pathways and plays a critical role in the regulation of water and electrolyte balance, blood pressure, and pain. Its complex biology and expressed expression in multiple tissues make it a potential drug target and biomarker for a variety of diseases.

Targeting INHBA with small molecules has the potential to modulate its function and lead to new treatments for INHBA-related disorders. Further research is needed to fully understand the biology of INHBA and its potential as a drug target.

Protein Name: Inhibin Subunit Beta A

Functions: Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins

More Common Targets